Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication

 
• By Joseph Haas
3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Kite obtains its second FDA approval for cell therapy Tecartus

More from New Products

More from Scrip